We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




CART Protein May Neutralize Cocaine

By Biotechdaily staff writers
Posted on 17 Dec 2003
A recent study into the metabolism of cocaine and other psychostimulant drugs found that a CART (cocaine-amphetamine regulated transcript) peptide reduced some of the effects of cocaine when it was injected into the locomotor area of the brain prior to the administration of the drug. More...


Investigators at Emory University (Atlanta, GA, USA; www.emory.edu) injected CART 55-102 into the nucleus accumbens area of the brains of a subject group of rats. They reported in the December 2003 issue of the Journal of Pharmacology and Experimental Therapeutics that injection of the peptide alone had no effect, but pretreatment with the peptide blunted or reduced the locomotor-inducing effects of cocaine. This effect was dose-related and time limited. A CART peptide fragment not active in other studies was without effect on cocaine-induced locomotor activity. Intra-accumbal injection of dopamine produced a dose-related and time-limited increase in locomotor activity. Co-injection of CART 55-102 with dopamine blunted the effect.

"Past studies have shown CART peptide is slightly cocaine-like in other areas of the brain, but nevertheless inhibits further stimulation from the drug,” explained senior author Dr. Michael Kuhar, chief of the neuroscience division at Emory University. "While additional research will be necessary, we have demonstrated the importance of CART peptide in combating or slowing down some of the effects of cocaine.”




Related Links:
Emory University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.